title: Oncosuppressive suicide gene virotherapy "PVH1-yCD/5-FC" for pancreatic peritoneal carcinomatosis treatment: NFκB and Akt/PI3K involvement.
abstract: Peritoneal carcinomatosis is common in advanced pancreatic cancer. Despite current standard treatment, patients with this disease until recently were considered incurable. Cancer gene therapy using oncolytic viruses have generated much interest over the past few years. Here, we investigated a new gene directed enzyme prodrug therapy (GDEPT) approach for an oncosuppressive virotherapy strategy using parvovirus H1 (PV-H1) which preferentially replicates and kills malignant cells. Although, PV-H1 is not potent enough to destroy tumors, it represents an attractive vector for cancer gene therapy. We therefore sought to determine whether the suicide gene/prodrug system, yCD/5-FC could be rationally combined to PV-H1 augmenting its intrinsic oncolytic activity for pancreatic cancer prevention and treatment. We showed that the engineered recombinant parvovirus rPVH1-yCD with 5-FC treatment increased significantly the intrinsic cytotoxic effect and resulted in potent induction of apoptosis and tumor growth inhibition in chemosensitive and chemoresistant cells. Additionally, the suicide gene-expressing PV-H1 infection reduced significantly the constitutive activities of NFκB and Akt/PI3K. Combination of their pharmacological inhibitors (MG132 and LY294002) with rPVH1-yCD/5-FC resulted in substantial increase of antitumor activity. In vivo, high and sustained expression of NS1 and yCD was observed in the disseminated tumor nodules and absent in normal tissues. Treatment of mice bearing intraperitoneal pancreatic carcinomatosis with rPVH1-yCD/5-FC resulted in a drastic inhibition of tumor cell spreading and subsequent increase in long-term survival. Together, the presented data show the improved oncolytic activity of wPV-H1 by yCD/5-FC and thus provides valuable effective and promising virotherapy strategy for prevention of tumor recurrence and treatment. In the light of this study, the suicide gene parvovirotherapy approach represents a new weapon in the war against pancreatic cancer. Moreover, these preliminary accomplishments are opening new field for future development of new combined targeted therapies to have a meaningful impact on advanced cancer.
authors: Biologie des Tumeurs, Université de Strasbourg, Strasbourg, France.
authors: Soukaina
authors: S
authors: Réjiba
authors: Christelle
authors: C
authors: Bigand
authors: Celine
authors: C
authors: Parmentier
authors: Ahmed
authors: A
authors: Masmoudi
authors: Amor
authors: A
authors: Hajri
mesh_terms: D000818:Animals; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D043525:Cytosine Deaminase / Q000235:genetics* / Q000378:metabolism; D004274:DNA, Recombinant / Q000235:genetics; D005260:Female; D005437:Flucytosine / Q000378:metabolism*; D041722:Genes, Transgenic, Suicide / Q000235:genetics*; D052661:H-1 parvovirus / Q000235:genetics* / Q000502:physiology; D006801:Humans; D051379:Mice; D016328:NF-kappa B / Q000378:metabolism; D020360:Neoadjuvant Therapy; D009361:Neoplasm Invasiveness; D050130:Oncolytic Virotherapy / Q000379:methods*; D010190:Pancreatic Neoplasms / Q000235:genetics / Q000473:pathology* / Q000628:therapy* / Q000821:virology; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism; D011355:Prodrugs / Q000378:metabolism; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects / Q000235:genetics; D015003:Yeasts / Q000201:enzymology
chemical_list: D004274:DNA, Recombinant; D016328:NF-kappa B; D011355:Prodrugs; D005437:Flucytosine; D019869:Phosphatidylinositol 3-Kinases; D051057:Proto-Oncogene Proteins c-akt; D043525:Cytosine Deaminase
references: Neoplasia. 2009 Jul;11(7):637-50
references: 19568409
references: J Clin Invest. 2005 Oct;115(10):2625-32
references: 16200195
references: J Virol. 1998 Nov;72(11):8893-903
references: 9765434
references: Proc Natl Acad Sci U S A. 1994 Aug 16;91(17):8302-6
references: 8058798
references: Oncology. 2002;62(4):354-62
references: 12138244
references: EMBO J. 2003 Jun 2;22(11):2552-60
references: 12773372
references: Cancer Res. 2000 Nov 15;60(22):6359-66
references: 11103798
references: Arch Virol. 1984;82(3-4):137-48
references: 6095787
references: Semin Oncol. 1996 Apr;23(2):241-50
references: 8623060
references: Nature. 2004 Sep 23;431(7007):461-6
references: 15329734
references: Hum Gene Ther. 2002 Sep 20;13(14):1737-50
references: 12396626
references: Hum Gene Ther. 1999 Jul 1;10(10):1619-32
references: 10428207
references: Proc Soc Exp Biol Med. 1965 Jul;119:711-5
references: 14328982
references: Cancer Res. 1999 Sep 1;59(17):4369-74
references: 10485485
references: J Virol. 2010 Jun;84(12):5909-22
references: 20375165
references: Biotechniques. 1994 May;16(5):876-81
references: 8068342
references: Nat Rev Microbiol. 2008 Jul;6(7):529-40
references: 18552863
references: Cancer Chemother Pharmacol. 2012 Jun;69(6):1601-15
references: 22543857
references: Cancer Gene Ther. 2002 May;9(5):432-42
references: 11961666
references: Blood. 1990 Feb 1;75(3):603-10
references: 2404522
references: Virology. 1993 Dec;197(2):770-3
references: 8249299
references: Biochim Biophys Acta. 2008 Apr;1785(2):217-31
references: 18328829
references: Hum Gene Ther. 2000 Mar 1;11(4):597-609
references: 10724038
references: J Natl Cancer Inst. 2011 Aug 3;103(15):1190-204
references: 21743023
references: Int J Mol Med. 2002 Oct;10(4):513-6
references: 12239603
references: Nat Rev Drug Discov. 2004 Jan;3(1):17-26
references: 14708018
references: Gene Ther. 2003 Aug;10(15):1241-7
references: 12858189
references: J Virol. 1999 May;73(5):3877-85
references: 10196282
references: Endocr Relat Cancer. 2006 Jun;13(2):607-16
references: 16728586
references: Int J Cancer. 1998 Feb 9;75(4):584-9
references: 9466660
references: Can J Gastroenterol. 2002 Feb;16(2):117-20
references: 11875596
references: Mol Cell Biol. 2007 Jun;27(11):3920-35
references: 17403902
references: Cancer Gene Ther. 2004 Jan;11(1):16-27
references: 14681723
references: Clin Cancer Res. 2006 Nov 15;12(22):6737-47
references: 17121894
references: Cancer Res. 1989 Jun 15;49(12):3203-8
references: 2541900
references: Oncogene. 2003 May 22;22(21):3243-51
references: 12761494
references: J Virol. 1988 Sep;62(9):3438-44
references: 3404581
references: Gene Ther. 2002 Jul;9(13):844-9
references: 12080378